Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Extraintestinal manifestations are frequent in inflammatory bowel diseases (IBD). Most studies published so far focused on viral hepatitis and liver toxicity of IBD-related drugs. AIM: To conduct a systematic review of hepatobiliary manifestations associated with IBD. We excluded viral hepatitis and liver toxicity of IBD-related drugs. METHODS: Studies were identified through the electronic database of MEDLINE, EMBASE and the annual meetings of Digestive Disease Week, the American College of Gastroenterology, the United European Gastroenterology Week and the European Crohn's and Colitis Organization. RESULTS: One hundred and forty six articles were included in this systematic review. Cholelithiasis is more frequent in Crohn's disease (CD) than in general population. Prevalence of cholelithiasis in CD ranged from 11% to 34%, whereas it ranges from 5.5% to 15% in non-IBD patients. PSC is more frequent in UC than in CD. Prevalence of PSC ranges from 0.76% to 5.4% in UC and from 1.2% to 3.4% in CD. There is a male predominance when PSC is associated with UC, with a male/female ratio ranging from 65/35 to 70/30. No conclusion can be made on a possible increased risk of gall-bladder carcinoma. Mean prevalence of fatty liver is 23% (range, 1.5-55%). Hepatic amyloidosis occurs in less than 1% of IBD. Liver abscess is encountered mainly in CD. Portal vein thrombosis occurs in 39% to 45% of IBD patients undergoing proctocolectomy. CONCLUSIONS: Hepatobiliary manifestations associated with inflammatory bowel diseases are frequent and probably underdiagnosed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence and Trends in Obesity Among US Adults, 1999-2008
Flegal, K. M. (2010) · JAMA · doi:10.1001/jama.2009.2014 · Cited by 7,580
Gregorio, G. (2001) · Hepatology · doi:10.1053/jhep.2001.22131 · Cited by 692 · cited 2×
“with AIH, two different features of the disease were identified.(157) It was called AIH and autoimmune sclerosing cholangitis (ASC) when radiological features”
Alabraba, E., Nightingale, P., Gunson, B., Hubscher, S., Olliff, S., Mirza, D., & Neuberger, J. (2009) · Liver Transplantation · doi:10.1002/lt.21679 · Cited by 298 · cited 20×
“Its prevalence seems to be higher in IBD than in general population.136 Concerning granulomatous hepatitis, only few cases related to IBD, both with UC and CD, have been reported.137 It seems to be idiopathic granulomatous hepatitis rather than CD metastasis, based on pathology reports and on the fact that it can affe…”
InfluentialClinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome
Floreani, A., Rizzotto, E. R., Ferrara, F., Carderi, I., Caroli, D., Blasone, L., & Baldo, V. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41841.x · Cited by 230
Lundqvist, K., & Broomé, U. (1997) · Diseases of the Colon & Rectum · doi:10.1007/bf02258391 · Cited by 159
Abnormal hepatic biochemistries in patients with inflammatory bowel disease
Mendes, F. D., Levy, C., Enders, F. B., Loftus, E. V., Angulo, P., & Lindor, K. D. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00947.x · Cited by 147
Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis
MOAYYERI, A., DARYANI, N. E., BAHRAMI, H., HAGHPANAH, B., NAYYER‐HABIBI, A., & SADATSAFAVI, M. (2005) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.03727.x · Cited by 60
Cited by
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
Rogler, G., Singh, A., Kavanaugh, A., & Rubin, D. T. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.042 · Cited by 869
A comprehensive review and update on ulcerative colitis,
Gajendran, M., Loganathan, P., Jimenez, G., Catinella, A. P., Ng, N., Umapathy, C., Ziade, N., & Hashash, J. G. (2019) · Disease-a-Month · doi:10.1016/j.disamonth.2019.02.004 · Cited by 638
Barberio, B., Massimi, D., Cazzagon, N., Zingone, F., Ford, A. C., & Savarino, E. V. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.08.032 · Cited by 152
Self-citationNordenvall, C., Olén, O., Nilsson, P. J., von Seth, E., Ekbom, A., Bottai, M., Myrelid, P., & Bergquist, A. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14393 · Cited by 78
“PSC-IBD is characterised by a more quiescent disease, a higher prevalence of pancolitis, backwash ileitis, rectal sparing and an increased risk of colorectal cancer than in UC alone.(3,4) Patients with a more aggressive PSC-disease requiring liver transplantation (LT) have been shown to have a milder IBD with less nee…”
BackgroundAltwegg, R., Combes, R., Laharie, D., De Ledinghen, V., Radenne, S., Conti, F., Chazouilleres, O., Duvoux, C., Dumortier, J., Leroy, V., et al. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.02.014 · Cited by 34
Self-citationNordenvall, C., Olén, O., Johan Nilsson, P., Ekbom, A., Bottai, M., Myrelid, P., & Bergquist, A. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izx048 · Cited by 18
Metadata
- Authors
- Gizard, E., Ford, A. C., Bronowicki, J.-P., & Peyrin-Biroulet, L.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2014-05-11
- Volume
- 40
- Issue
- 1
- Pages
- 3-15
- ISSN
- 0269-2813 (ISSN-L)
- OpenAlex
- W1973712938
- Cited by
- 139
- References
- 7
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.